StockData
Foghorn Therapeutics Inc. logo

Foghorn Therapeutics Inc. (FHTX) stock

FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/30
$1.79−0.04 (-2.19%)

Close on Nov 18, 2026Market cap $106.30MP/E –Yield –

Foghorn Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Foghorn Therapeutics

Foghorn Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Foghorn Therapeutics figures

See a number that looks wrong?